{
  "_id": "NCT00042588",
  "title": "A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis",
  "text": "Summary: The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.\nInclusion criteria: inclusion criteria: \n\n Current diagnosis of community-acquired pneumonia. \n\n Evidence of systemic inflammatory response to infection. \n\n \nExclusion criteria: : \n\n Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator. \n\n Presence of organ failure.",
  "metadata": {
    "brief_title": "A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis",
    "phase": "Phase 2",
    "drugs": "['Recombinant Chimeric Monoclonal Antibody']",
    "drugs_list": [
      "Recombinant Chimeric Monoclonal Antibody"
    ],
    "diseases": "['Pneumonia', 'Sepsis']",
    "diseases_list": [
      "Pneumonia",
      "Sepsis"
    ],
    "enrollment": "",
    "inclusion_criteria": "inclusion criteria: \n\n Current diagnosis of community-acquired pneumonia. \n\n Evidence of systemic inflammatory response to infection. \n\n ",
    "exclusion_criteria": ": \n\n Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator. \n\n Presence of organ failure.",
    "brief_summary": "The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis."
  }
}